The effect of cervical transcutaneous electrical neurostimulation on cerebral blood flow velocities, cerebral vasospasm and ischemic deficit in secondary cerebral vasospasm after subarachnoid haemorrhage

The effect of cervical transcutaneous electrical neurostimulation on cerebral blood flow velocities, cerebral vasospasm and ischemic deficit in secondary cerebral vasospasm after subarachnoid haemorrhage - Cervical TENS in cerebral vasospasm

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34128

Enrollment

Registered

2010-05-26

Start date

2010-09-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral vasospasm spasm of the vessels in the brain

Interventions

Cervical TENS applied at different frequencies.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Confirmed aneurysmatic subarachnoid hemorrhage. Cerebral vasospasm demonstrated by TCD, defined as a MCA/ICA ratio >3 Aneurysm is treated with a surgical or endovascular procedure. Age > 18 years. Treatment can be started promptly. Informed consent signed by patient or family.

Exclusion criteria

Exclusion criteria: History of cervical spine or skull-base surgery. Known adverse reaction to TENS-pads. The presence of any implanted electronic device (including pacemakers). Pre-existing disease that can obscure follow-up. Unacceptable interference with cardiographic registration (in case intensive care is necessary). Insuficient temporal bony windows

Design outcomes

Primary

Measure	Time frame
Cerebral bloodflowvelocities as measured by transcranial doppler sonography	—

Secondary

Measure	Time frame
Cerebral ischemia as seen on computed tomography scans Cerebral oxygenationas measured by near-infrared spectroscopy Bloodpressure and pulse. Clinical outcome.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)